

List of Ohio State Experts at 2026 AACR® Annual Meeting

Virology and Cancer

Sunday, April 19, 2026, 2 p.m. – 5 p.m.

Section 10

Presentation number: 221

Poster number: 16

Single-cell ATAC-sequencing Profiling of HPV18 Positive Head and Neck Cancer Cells Reveals Heterogeneity of HPV18 Genome Accessibility and its Association with Cancer Progression

Authors: **Chongwen Cao**¹, Weiyi Gong², Haichang Li², Bo Zhao³, Qingqing Wu², Priyanka Bhateja², Dukagjin Blakaj², Jenny Li², Xuefeng Liu¹

Application of Bioinformatics to Cancer Biology 1

Sunday, April 19, 2026, 2 p.m. – 5 p.m.

Section 3

Presentation number: 63

Poster number: 25

Intratumoral *Candida albicans* associates with Hypoxia and Poor Outcomes in Non Small Cell Lung Cancer (NSCLC)

Authors: **Dipankor Chatterjee**¹, Dennis J. Grencewicz², Alexander Loncar³, Ruohan Wu⁴, Alex Samouilov², Sylvain Ferrandon⁵, McKenzie Creamer⁶, Yogita Mehra⁷, Aspen Carson⁸, Rebecca Hoyd⁸, Shiva Jahanbakhshi⁸, Fouad Choueiry⁶, Matthew Anderson⁹, Martin Benej¹⁰, Dustin Bosch¹¹, Jiangjiang (Chris) Zhu³, Jinghai Wu¹², Thérèse Bocklage¹³, Martin McCarter¹⁴, Ahmad Tarhini¹⁵, Bodour Salhia¹⁶, Christopher A. Moskaluk¹⁷, Gregory Riedlinger¹⁸, Song Yao¹⁹, Ashiq Masood²⁰, Sheetal Hardikar²¹, Mmadili N. Ilozumba²², Cornelia M. Ulrich²¹, Abdul Rafeh Naqash²³, Carlos H.F. Chan²⁴, Craig D. Shriver²⁵, Dinesh Pal Mudaranthakam²⁶, Aaditya Pallerla²⁷, Michelle Churchman²⁸, Robert J. Rounbehler²⁹, Laura Chambers⁷, Matthew F. Kalady⁵, Nicholas C. Denko³⁰, David P. Carbone³¹, Dan Spakowicz⁸

Presentation number: 43

Poster number: 5

Epigenetic-Neurotransmitter Crosstalk between EZH2 and Dopamine D1 Receptor Signaling in Triple-Negative Breast Cancer

Authors: **Maciej Pietrzak**¹, Xilal Y. Rima², Gautam Sarathy³, Shivani Dhekne³, Lara Rizotto⁴, Dario Palmieri⁴, Sanjay Gupta⁵, Daniel G. Stover⁶, Giovanni Nigita⁷, Eduardo Reátegui², Pierre Giglio⁸, Christian Rolfo⁷, Eswar Shankar³

Survivorship Research Addressing Cancer Disparities

Sunday, April 19, 2026, 2 p.m. – 5 p.m.

Section 35

Presentation number: 916

Poster number: 29

Prevalence of Screen-Detectable Cancers Among Adults Aged 18-49 Years: Findings from HINTS-SEER

Authors: Gaurav Y. Kulkarni¹, Matthew Untalan¹, Wayne R. Lawrence², Ami E. Sedani³, Subhankar Chakraborty⁴, Dede K. Teteh-Brooks⁵, **Aldenise P. Ewing⁶**

Presentation number: 905

Poster number: 18

Racial Disparities in Geographic Access to Uterine Cancer Clinical Trials Across U.S. Counties

Authors: Caitlin E. Meade¹, Jennifer A. Sinnott², Simran A. Kanai¹, Laura M. Chambers³, **Ashley S. Felix¹**

Presentation number: 912

Poster number: 25

Non-Hodgkin's Lymphoma Survival by Neighborhood Disinvestment and Socioeconomic Composition

Authors: **Jesse J. Plascak**, Elizabeth Ghias, Daniel C. Trotier, James L. Fisher, Kami J. Maddocks, Jennifer A. Woyach

Experimental Chemoprevention and Interception: Data and Tools

Sunday, April 19, 2026, 2 p.m. – 5 p.m.

Section 37

Presentation number: 962

Poster number: 21

Phenylacetaldehyde Induces Apoptosis through Endoplasmic Reticulum Stress and Potentiates the Effect of 5-FU Treatment in Colorectal Cancer

Authors: **Sylvain Ferrandon¹**, Cheng Kong², sara soltani tehrani¹, Joseph Fedro¹, Rami-James Aoun¹, Zeneng Wang³, Chureeporn Chitchumroonchokchai¹, Huanlong Qin⁴, Steve Clinton¹, Matthew F. Kalady¹

RNA, Gene and Cell Therapies, and Enabling Assay Technologies

Sunday, April 19, 2026, 2 p.m. – 5 p.m.

Section 19

Presentation number: 468

Poster number: 11

Leveraging Single-Cell Multiomics for a Generalizable Approach to Differentiation Therapy

Authors: **Scott C. Friedland**¹, Tianli Ding², Gary Schweickart², Alice Mims³, Katherine Miller², Adithe Rivaldi², Elizabeth Garfinkle², Sunkel Benjamin², Jaye Navarro², Michelle Wedemeyer⁴, Ann-Kathrin Eisfeld³, Elaine R. Mardis⁵

Targeting Mitochondria and Metabolic Vulnerabilities for Cancer Therapy

Sunday, April 19, 2026, 2 p.m. – 5 p.m.

Section 23

Presentation number: 557

Poster number: 9

TRAP1 Represents a Mitochondrial Target and Biomarker of Dedifferentiated Liposarcoma

Authors: **Roma Karna**¹, Esin Ulker², Sydney Rentsch¹, Marina Capece¹, Sayumi Tahara¹, Qi Zhang¹, Patricia Sarchet¹, Giovanni Nigita¹, Paolo Fadda¹, Fernanda Costas Casal de Faria¹, Valerie Grignol¹, Nicholas C. Denko², Carlo M. Croce³, Raphael E. Pollock¹, Federica Calore¹

Biomarkers Predictive of Therapeutic Benefit 2

Sunday, April 19, 2026, 2 p.m. – 5 p.m.

Section 41

Presentation number: 1043

Poster number: 11

MUC5AC Expression Defines an Immune-Inflamed but Functionally Restrained Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma

Authors: **Ashish Manne**¹, Wancai Yang¹, Yongchen Guo¹, Vaibhav Sahai², Prachi Bajpai³, Yonghua Bao¹, M Khalid Khan Niazi¹, Alejandro Leyva¹, Upender Manne³

Prognostic Biomarkers 1

Sunday, April 19, 2026, 2 p.m. – 5 p.m.

Section 46

Presentation number: 1196

Poster number: 20

A pre-treatment cfDNA Methylation Signature Linking Prognosis and Drug-Resistance Biology in Pancreatic Ductal Adenocarcinoma

Authors: **Ashish Manne**¹, Lianbo Yu¹, Wancai Yang¹, M Khalid Khan Niazi¹, Ravi Paluri², Anup Kasi³, Prachi Bajpai⁴, Alejandro Leyva¹, Upender Manne⁴

Biomarkers of Endogenous or Exogenous Exposures, Early Detection, Biological Effects, and Prognosis

Monday, April 20, 2026, 9 a.m. – noon

Section 35

Presentation number: 2307

Poster number: 6

Body Mass Index-Associated Transcriptomic Signatures Reveal Immune, Stromal, and Metabolic Rewiring in Non-Small Cell Lung Cancer: Insights into the Obesity Paradox

Authors: **Roberto Borea**, Eswar Shankar, Francesco Drago, Carlos Ayala de Miguel, Estela Puchulu-Campanella, Christian Rolfo, Giovanni Nigita

MicroRNAs as Cancer Biomarkers, Therapeutic Targets, and Modulators of Treatment Response

Monday, April 20, 2026, 9 a.m. – noon

Section 25

Presentation number: 2055

Poster number: 15

Isoform-aware miRNA Network Mapping in NSCLC via Computational Consensus Targeting and Functional Clustering

Authors: **Shaopeng Gu**¹, Junhao Liu², Shaohong Feng³, Rosario Distefano⁴, Sebastiano Di Bella⁵, Francesco Orilio⁵, Rosario Brancaccio⁵, Giulia Romano⁶, Eswar Shankar⁷, Mario Acunzo⁶, Federica Calore⁸, Christian Rolfo⁷, Qin Ma¹, Giovanni Nigita⁷

Integrative Computational Approaches 1

Monday, April 20, 2026, 9 a.m. – noon

Section 5

Presentation number: 1488

Poster number: 27

Structure-Guided Dual Targeting of EZH2 and Dopamine D1 Receptor Suppresses TNBC Growth and Metastasis

Authors: **Francesco Drago**¹, Libere Ndacayisaba², Xilal Y. Rima³, Gautam Sarathy¹, Deborah Ramsey⁴, Gwen Fewell⁴, Senthil Saravanamuthu², Sanjay Gupta⁵, Giovanni Nigita¹, Eduardo Reátegu³, Pierre Giglio⁶, Christian Rolfo¹, Eswar Shankar¹

Metabolic and Transcriptional Control of Cancer Stem Cell Plasticity

Monday, April 20, 2026, 9 a.m. – noon

Section 30

Presentation number: 2193

Poster number: 12

UPP1 Promotes Cisplatin-Induced Cancer Stem Cell Enrichment in Ovarian Cancer Via Metabolic Reprogramming

Authors: **Jessica J. Miao**¹, Linzhou Wang¹, Ananya Banerjee¹, Na Li¹, Yajing Yang¹, Aidan Li¹, Kevin Wang², Patrick Stevens², Xiaoli Zhang³, Qi-En Wang¹

Sequence Analysis

Monday, April 20, 2026, 9 a.m. – noon

Section 6

Presentation number: 1509

Poster number: 16

Cost-Effective, Full-Length Transcriptome of Chronic Lymphocytic Leukemia Patient CD8 T Cells Reveals the Impact of BTKi Treatment on mRNA Processing and Gene Expression

Authors: Shanmugapriya Thangavadivel¹, Altan Turkoglu¹, Lianbo Yu¹, Rosario Distefano¹, Alexander Pan², Logan Walker³, Tina Wang⁴, Shrilekha Misra¹, Tzung-Huei Lai¹, Britten Gordon¹, Samon Benrashid¹, Alexander He¹, Meixiao Long¹, rosa Lapalombella¹, John C. Byrd⁵, Kerry A. Rogers¹, Bradley Blaser¹, Ralf Bundschuh⁶, Jennifer A. Woyach¹, **Pearlly S. Yan**¹

Late-Breaking Research: Immunology 2

Monday, April 20, 2026, 9 a.m. – noon

Section 53

Presentation number: LB150

Poster number: 15

Senescence as an Immune Tolerance Breaker: Inhibitors of Mitotic Kinases TTK (Mps1) and AURKA Induce Pro-Immunogenic Senescence that Primes the Tumor Microenvironment for Immunotherapy via cGAS-STING Signaling

Authors: Marina Capece, Evdokiya Reshetnikova, Yinchong Wang, Arjun Mittra, **Anna E. Vilgelm**

Metabolism and Microbiome in Cancer Initiation and Prevention

Monday, April 20, 2026, 2 p.m. – 5 p.m.

Section 36

Presentation number: 3635

Poster number: 21

Interim Results of the BEFIT Exercise Intervention Pilot Study to Assess the Microbiome and Immune Function in a High-Risk Cohort for Lung Cancer

Authors: **Marisa Bittoni**, Zachary Chaplow, Daniel Spakowicz

Presentation number: 3618

Poster number: 4

Obesity-Mediated Extracellular Vesicle Secretion as a Targetable Driver of Endometrial Cancer Initiation and Progression

Authors: **Lakshmi Narasimhan Chakrapani**¹, Kalapana Deepa Priya Dorayappan¹, Ganesh Yadagiri¹, Shyam Sundaram¹, Gabriela S. Vendrell¹, Takahiko Sakaue², Jessica Velasquez¹, Xavier Ryon Washington Ramesh³, Thangavel Muthusamy⁴, Casey M. Cosgrove¹, David E. Cohn¹, David M. O'Malley¹, Selvendiran Karuppayiah¹

Microbiome, Inflammation, and Response to Immunotherapy in Cancer

Monday, April 20, 2026, 2 p.m. – 5 p.m.

Section 9

Presentation number: 2861

Poster number: 1

Comparative Genomics of Gut Commensal *Lachnospiraceae* and their Associations with Cancer Treatment Response with Immune Checkpoint Inhibitors

Authors: **Shiva Jahanbakhshi**, Amna Bibi, Rebecca Hoyd, Caroline Dravillas, Nyelia Williams, Shiqi Zhang, Aaditya Pallerla, Shankar Suman, Joseph Amann, Mounika Goruganthu, Tamio Okimoto, Yangyang Liu, Marisa A. Bittoni, Ni Shi, Alvin Anand, Bailey Conrad, Lane Nevers, Kristen Heitman, Maxine Webb, Elizabeth M. Grainger, Madison Grogan, Christian Quiles, Tong Chen, Carolyn J. Presley, Lang Li, Patrick Bradley, Yael Vodovotz, David P. Carbone, Steven K. Clinton, Jiangjiang Zhu, Daniel Spakowicz

Radiomics and AI in Medical Imaging

Monday, April 20, 2026, 2 p.m. – 5 p.m.

Section 4

Presentation number: 2771

Poster number: 2

Integrating Image and Text-Based AI Improves Identification of Metastatic Sites from Whole-Slide Pathology Images

Authors: **Yixin Chen**¹, Ziyu Su¹, Muhammad Khalid Niazi¹, Anil Vasdev Parwani², Elshad Hasanov¹

Extracellular Vesicles and Long-Range Tumor-Host Communication

Monday, April 20, 2026, 2 p.m. – 5 p.m.

Section 26

Presentation number: 3347

Poster number: 8

Proteomic and Functional Divergence of Small and Large Extracellular Vesicles Reveal Subtype-Specific Drivers of Ovarian Cancer Progression

Authors: **Kalpana Deepa Priya Dorayappan**¹, Fries Brian², Wei Fu³, Ganesh Yadaigiri¹, Lakshmi Narasimhan Chakrapani¹, Sydney Wiggins⁴, Shyam Sundaram⁵, Thangavel Muthusamy⁶, Sudhiksha Anbu Chelian⁷, Gabriela S. Vendrell², Qi-En Wang⁸, David E. Cohn¹, Lianbo Yu⁹, David O'Malley¹, Colin Hisey⁴, Selvendiran Karuppayah¹

Presentation number: 3348

Poster number: 9

Liposarcoma-Derived Extracellular Vesicles Suppress STING Signaling and Impair Innate Immune Activation in Macrophages

Authors: **Qi Zhang**, Patricia Sarchet, Fernanda C. C. de Faria, Priya Dhawale, Sydney Rentsch, Roma Karna, Valerie Grignol, Jing Wang, Raphael Pollock, Federica Calore

Prognostic Biomarkers 2

Monday, April 20, 2026, 2 p.m. – 5 p.m.

Section 48

Presentation number: 3941

Poster number: 16

A RHO GTPase Pathway Signature as a Potential Prognostic Biomarker and Therapeutic Target in Bladder Cancer

Authors: **Weiyi Gong**¹, Chongwen Cao², Peng Wang³, Shang-Jui Wang⁴, Akshay Sood⁵, Lingbin Meng³, Qingqing Wu⁶, Cheryl Lee⁵, Anil Vasdev Parwani⁶, Jenny Li⁶, Xuefeng Liu⁷

Modifiers of Inflammation and the Tumor Microenvironment

Monday, April 20, 2026, 2 p.m. – 5 p.m.

Section 10

Presentation number: 2893

Poster number: 3

Selective Inhibition of eIF4A Targets Tumor-Associated Macrophages to Restore Lymphoma-Specific Immunity

Authors: **Haley Lynn Klimaszewski**¹, A. Douglas Kinghorn², Michael R. Grever³, Robert A. Baiocchi³, John T. Patton³

Large Language Models in the Clinic

Monday, April 20, 2026, 2 p.m. – 5 p.m.

Section 3

Presentation number: 2743

Poster number: 7

Deploying Artificial Intelligence Driven Digital Pathology for Real World Clinical Decision-Making in Pancreatic Cancer

Authors: **Ashish Manne**¹, Alejandro Leya¹, Abdul Rehman Akbar¹, Upender Manne², Anne Noonan¹, Anup Kasi³, Ashwini Eshakula¹, Ravi Paluri⁴, Anil Vasdev Parwani⁵, Muhammad Khalid Khan Niazi¹

Cellular Responses to Anticancer Drugs

Monday, April 20, 2026, 2 p.m. – 5 p.m.

Section 11

Presentation number: 2928

Poster number: 5

KRAS Inhibition-Induced GSDME-Mediated Pyroptosis and its Augmentation by LAT1 Inhibition in KRAS-Mutant Lung Cancer

Authors: **Kenji Morimoto**, Ju Hwan Cho, Po-Lan Su, Peiran Xu, Andrew Barnes, Rahul Shivahare, Jacob Kaufman, Zihai Li, David Paul Carbone, Kai He

Application of Bioinformatics to Cancer Biology 3

Monday, April 20, 2026, 2 p.m. – 5 p.m.

Section 1

Presentation number: 2695

Poster number: 20

HELP-TCR: A Harmonized and Explainable Language Processing Framework for Functional Analysis of T-Cell Receptor Repertoires

Authors: Yulyana Kalesnik¹, Dawid Krawczyk², **Maciej Pietrzak**³, Michal Seweryn⁴

Molecular Classification and Tumor Biology in Cancer

Monday, April 20, 2026, 2 p.m. – 5 p.m.

Section 46

Presentation number: 3871

Poster number: 4

Molecular Correlates of Response and Survival in a Phase II Trial of Weekly Carboplatin/Paclitaxel Plus Cemiplimab (wCP+C) in Advanced/Metastatic Mucosal Head and Neck Squamous Cell Carcinoma (a/mHNSCC)

Authors: **Mateus Trinconi Cunha**¹, Fahad Rind², Priyanka Bhateja¹, Esmerina Tili³, David Konieczkowski⁴, Darrion Mitchell⁴, Sujith Baliga⁴, Sung Jun Ma⁴, Simeng Zhu⁴, Gogineni Emile⁴, John Grecula⁴, Nolan Seim⁵, Catherine Harring⁵, Lauren Miller⁵, Abberly Lott Limbach⁶, Kang Stephen⁵, James W. Rocco⁵, Christian Rolfo⁷, Dukagjin Blakaj⁴, Marcelo Bonomi⁸

Phase II and Phase III Clinical Trials

Monday, April 20, 2026, 2 p.m. – 5 p.m.

Section 52

Presentation number: CT155

Poster number: 19

Phase 1b trial of NG-350A, a CD40 Agonist Antibody Expressing Adenoviral Vector, in Combination with Chemoradiotherapy (CRT), in Patients with Mismatch Repair-Proficient (pMMR) Locally Advanced Rectal Cancer (LARC): Initial Results from the FORTRESS Study

Authors: **Eric D. Miller**¹, Pannaga Malalur¹, Sonal S. Noticewala², Arvind Dasari², Sheela Rao³, Andry Santoso³, Maria Hawkins⁴, Douglas Brand⁴, Rui Ru Ji⁵, Korinna Pilz⁶, Oliver Rosen⁵

Phase 0 and First-in-Human Phase I Clinical Trials

Monday, April 20, 2026, 2 p.m. – 5 p.m.

Section 52

Presentation number: CT118

Poster number: 10

Clinical Pharmacokinetic and Pharmacodynamic of JBZ-001 (HOSU-53): Comparison of First-In-Human Data with Translational Preclinical Predictions

Authors: **Min Hai**¹, Nicole Abbott², James O. Larkin², Zhiliang Xie², Christopher Coss¹, Tamara Jovonovich³, Zuzana J. Trnkova³, Philippa Graham⁴, William B. McKean⁵, Asrar A. Alahmadi², Mitch Phelps¹

Novel Antitumor Agents 2

Tuesday, April 21, 2026, 9 a.m. – noon

Section 17

Presentation number: 4577

Poster number: 20

Targeting midkine-driven oncogenic signaling with HBS-101: A novel therapeutic strategy for lung cancer

Authors: **Roberto Borea**¹, Francesco Drago¹, Malaak Sammour², Nigita Giovanni², Serena Li Zhao³, Blake R. Peterson⁴, Hareesh B. Nair⁵, Christian Rolfo², Eswar Shankar²

Precision Oncology and Real World Data

Tuesday, April 21, 2026, 9 a.m. – noon
Section 46

Presentation number: 5352

Poster number: 20

Genomic and Ancestry-Associated Determinants of Survival in Gynecologic Cancers

Authors: **Laura Chambers**¹, Avinash Ramu², Vasily N. Aushev², Susan Rojahn², Alyssa Antonopoulos², Carly B. Scalise², Faraz Salmasi², Minetta C. Liu², Adam C. ElNaggar², Rebecca C. Arend³

Prognostic Biomarkers 3

Tuesday, April 21, 2026, 9 a.m. – noon
Section 47

Presentation number: 5364

Poster number: 2

Neutrophilic Skin Infiltrates in Patients with Acute Myeloid Leukemia (AML) Are Clonal and Associate with Poor Overall Survival

Authors: Gabby Tesfaye¹, Yazan Abu-Shihab¹, Deedra Nicolet², Jill Buss², Andrea Laganson², Catherine Chung², SANAM LOGHAVI², Benjamin Kaffenberger³, **Ann-Kathrin Eisfeld**⁴

Epigenetic Modulators 1

Tuesday, April 21, 2026, 9 a.m. – noon
Section 14

Presentation number: 4490

Poster number: 9

PRMT5 Inhibition Alters Cellular Chromatin Landscape And Drives Vulnerability to BH3 Mimetics in Mantle Cell Lymphoma

Authors: **Christoph Weigel**¹, Claire Hinterschied¹, Shirsha Koirala¹, Mackenzie Long¹, Shelby Sloan¹, Jessica Weist¹, Lynda Villagomez², Allesandro La Ferlita¹, Coinne Gao¹, Ian Hout¹, Sydney Leon¹, Fiona Brown-Burke¹, Betsy Pray¹, Maggie Harper¹, Neha Bhagwat³, Kris Vaddi³, Peggy A. Scherle³, Cem Meydan⁴, Selina Chen-Kiang⁵, Maurizio

DiLiberto⁵, Olivier Elemento⁴, Christopher E. Mason⁴, Jihye Paik⁵, Lapo Alinari¹, Rosa Lapalombella¹, Lalit Sehgal¹, Robert Baiocchi¹

Fibroblasts as Architects of the Tumor Microenvironment

Tuesday, April 21, 2026, 2 p.m. – 5 p.m.

Section 25

Presentation number: 6044

Poster number: 21

Immunosuppressive Role of DKK1 and Cancer-Associated Fibroblasts Across Molecular Subtypes of Endometrial Cancer

Authors: Alessandro Canella¹, Danielle Glassman¹, Keith Brownell¹, Caprice Eisele², Aharon Gideon Freud², **Casey Cosgrove**¹

Inflammation, Immunity, and Cancer

Tuesday, April 21, 2026, 2 p.m. – 5 p.m.

Section 45

Presentation number: 6579

Poster number: 12

Investigating the Role of Signal Peptide Peptidase in Tumor Immune Evasion via Qa-1-Mediated Peptide Presentation

Authors: Roya Solhi¹, Clara Wolfe², Hu Chen¹, Achintya Perumal¹, Kyle Ockerman², Grant Brennan¹, Jiayao Ye¹, Adrienne H. Long², Marc Schwartz², Susan Klaeger², Steven A. Carr², Thorbald van Hall³, Jon A. Weidanz⁴, Soroush Ghaffari⁴, Kathleen B. Yates², Robert T. Manguso², Qin Ma¹, **Hakimeh Ebrahimi-Nik**¹

Presentation number: 6580

Poster number: 13

A Novel Regulator of T-cell Motility: Fhl2 Controls CD8⁺ T-cell Migration and Infiltration

Authors: Achintya Perumal¹, Grant Brennan¹, Jiayao Ye¹, Hu Chen¹, Roya Solhi¹, Omar I. Avila², Kathleen B. Yates², Robert T. Manguso², Stanley C. Huang¹, Haoxin Zhao¹, Giovanni Nigita¹, Zihai Li¹, No-Joon Song¹, Hazem E. Ghoneim¹, Ava Lowin¹, Kelley Ptak¹, Qin Ma¹, **Hakimeh Ebrahimi-Nik**¹

Environmental and Occupational Risk Factors, Infection, and Aging

Tuesday, April 21, 2026, 2 p.m. – 5 p.m.

Section 33

Presentation number: 6265

Poster number: 27

Association of Area Deprivation Index with Immune Functioning and History of Abnormal Cervical Screening among Appalachian Young Women

Authors: **Chloe M. Hery**¹, Yesung Kweon¹, Mohamed I. Elsaid¹, Cecilia DeGraffinreid¹, Mack T. Ruffin², Electra D. Paskett¹

Real World Data to Provide Real World Evidence

Tuesday, April 21, 2026, 2 p.m. – 5 p.m.

Section 47

Presentation number: 6645

Poster number: 14

Practice Patterns Impacting Relative Dose Intensity of Adjuvant Capecitabine Among Triple Negative Breast Cancer Patients with Residual Disease Following Neoadjuvant Chemotherapy

Authors: Andrea House, Pratik Thakur, Blair Hoeting, Ruth Johnson, Brittany Sandoval, Julie Stephens, Daniel G. Stover, Sagar Sardesai, Tanun Jitwatcharakomol, Sasha Beyer, Arya M. Roy, Nerea Lopetegui-Lia, Dionisia M. Quiroga, Ashley P. Davenport, Gilbert Bader, Nicole O. Williams, Robert Wesolowski, Margaret E. Gatti-Mays, **Kai C. Johnson**

Presentation number: 6646

Poster number: 15

Impact of Histology Subtypes (ductal, lobular, and mixed ductal/lobular) on Pathological Complete Response (pCR) following Neoadjuvant Chemotherapy (NAC) and Chemoimmunotherapy (NACI) for Estrogen Receptor Low (ER-low) HER2-negative Breast Cancer

Authors: **Kai C. C. Johnson**, Brandon Slover, Yengeniya Gokun, Dionisia M. Quiroga, Sagar Sardesai, Sachin Jhavar, Nerea Lopetegui-Lia, Arya M. Roy, Gilbert Bader, Ashley P. Davenport, Nicole O. Williams, Robert Wesolowski, Margaret E. Gatti-Mays, Daniel G. Stover

Vaccines and Other Immunomodulatory Agents

Tuesday, April 21, 2026, 2 p.m. – 5 p.m.

Section 49

Presentation number: 6707

Poster number: 18

Developing Oncolytic Measles Virus Expressing MG53 for the Treatment of Lung Cancer

Authors: Zhongguang Li¹, Cheng Chih Hsu¹, Fei Jiang¹, Matthew Bu¹, Ellica Leong¹, Umme Lubaba¹, Xuefeng Liu², Jianrong Li¹, **Haichang Li**¹

Presentation number: 6696

Poster number: 7

A senescent Whole-Cell Vaccine Platform Derived from Conditionally Reprogrammed Primary Tumor Cells Primes Potent T-cell Immunity and Overcomes ICI Resistance in Murine Breast Cancer Models

Authors: **Sara Rasouli**¹, Chongwen Cao², Weiyi Gong¹, Haichang Li³, Bei Liu⁴, Anna Vilgelm², Jenny Li², Xuefeng Liu²

T Cell Engagers 2 / Antibody-Drug Conjugates 1

Tuesday, April 21, 2026, 2 p.m. – 5 p.m.

Section 8

Presentation number: 5605

Poster number: 24

Advanced Dual Payload Antibody-Drug Conjugates for Targeted Chemoimmunotherapy

Authors: **X. Margaret Liu**, Zhuoxin “Zora” Zhou

Diagnostic Biomarkers 2

Tuesday, April 21, 2026, 2 p.m. – 5 p.m.

Section 43

Presentation number: 6529

Poster number: 18

Vaginal Microbiome Dynamics and Clinical Outcomes in Cervical Cancer Patients Undergoing Radiotherapy

Authors: **Yogita Mehra**¹, Julia Chalif², Elizabeth LaPlante³, Laura Flora³, Caroline Dravillas¹, January Kim³, Jessica Aduwo³, Naa Korley³, Nyelia Williams³, Rebecca Hoyd¹, David O'Malley², Elizabeth K. Arthur³, Allison M. Quick², Daniel Spakowicz¹, Laura Chambers²

Deep Learning in Cancer

Tuesday, April 21, 2026, 2 p.m. – 5 p.m.

Section 2

Presentation number: 5470

Poster number: 6

Low-Magnification Deep Learning Model for Rapid HER2 Status Prediction from H&E Whole-Slide Images

Authors: **Ziyu Su**¹, Abdul Rehman Akbar¹, Usama Sajjad¹, Sansar Babu Tiwari¹, Elshad

Hasanov², Arya Mariam Roy³, Zaibo Li¹, Daniel G. Stover⁴, Muhammad Khalid Khan Niazi¹

Therapeutic Modulation of the Tumor Microenvironment: New Targets and Approaches 2

Wednesday, April 22, 2026, 9 a.m. – noon
Section 29

Presentation number: 7463

Poster number: 14

Targeting S100A7/RAGE-driven Stat3/Serpin-E1 Signaling for Immunotherapy in Metastatic Breast Cancer

Authors: **Pratyusha Ghanta**¹, Ajeet K. Verma¹, Cho-Hao Lin¹, Manish Charan¹, Ganesh R. Koshre², Tanisha Mukherjee¹, Wayne O. Miles², Sanjay Mishra¹, Ramesh Ganju¹

Presentation number: 7473

Poster number: 24

A Novel Dual-Target Strategy Against TNBC: Combining EZH2 Inhibition and Dopamine D1 Receptor Activation to Restore Immune Balance

Authors: Rajni Kant Shukla¹, Kate Ormiston², Gautam Sarathy², Shivani Dhekne², Dionisia Marie Quiroga², Sanjay Gupta³, Daniel G. Stover⁴, Pierre Giglio⁵, Christian Rolfo², **Eswar Shankar**²

Translational Biomarkers and Emerging Molecular Approaches

Wednesday, April 22, 2026, 9 a.m. – noon
Section 48

Presentation number: 7897

Poster number: 2

Novel Rho-GTPase Regulatory Protein Gene Family Variants Are Frequent and Associate with Poor Survival in Patients (pts) with Acute Myeloid Leukemia (AML)

Authors: **Ethan Hamp**¹, Lorenz Oelschläger², Bailee N. Kain³, Deedra Nicolet⁴, Krzysztof Mrozek¹, Katherine E. Miller⁵, Audrey Bollas⁵, Michael C. Walker⁴, Christopher J. Walker¹, Jill Buss¹, Andrea Laganson¹, Andrew J. Carroll⁶, William G. Blum⁷, Bayard L. Powell⁸, Geoffrey L. Uy⁹, Wendy Stock¹⁰, Marina Y. Konopleva¹¹, Richard M. Stone¹², John C. Byrd¹³, Martin Carroll¹⁴, Tanmoy Sarkar¹⁴, Akmaljon Salimov¹⁴, Benjamin J. Kelly⁵, Electra D. Paskett¹, Jesse J. Plascak¹, Shannon McWeeney¹⁵, Jeffrey W. Tyner¹⁵, Jeffery Klco¹⁶, Nathan Salomonis³, H. Leighton Grimes³, Elaine R. Mardis⁵, Ann-Kathrin Eifeld¹

Presentation number: 7905

Poster number: 10

Dihydroorotate Dehydrogenase (DHODH) Inhibition as a Promising Therapeutic Strategy with Synergistic Targeting of ROR1 in Small Cell Lung Cancer

Authors: **Bahareh Nourmohammadi**¹, Ola A. Elgamel², Sandip Vibhute¹, Christopher C. Coss¹, Thomas E. Goodwin³, Erin Hertlein², Joseph M. Amann¹, Ju Hwan Cho¹, Chad E. Bennett¹, John C. Byrd², David P. Carbone¹

Drug Resistance 2: Tyrosine Kinase Inhibitors

Wednesday, April 22, 2026, 9 a.m. – noon

Section 11

Presentation number: 7039

Poster number: 18

FER Drives Drug-Tolerant Persister Cell Survival in EGFR-Mutant Lung Cancer

Authors: **Bobak Parang**¹, Rabia Khan², Ariana Kupai¹, Yuyun Huang¹, Sungyun Cho², Michal J. Nagiec², Eric E. Gardner², Florencia M. Rowdo², Benjamin D. Hopkins², Qin Fu³, Sheng Zheng³, Timothy F. Burns¹, John Blenis²

Biological Mechanisms of Tumor and Normal Tissue Response and Clinical Studies

Wednesday, April 22, 2026, 9 a.m. – noon

Section 26

Presentation number: 7379

Poster number: 16

FDXR Expression is a Rectal Cancer Biomarker of Radiation Resistance and Confers Resistance through Ferroptosis

Authors: **Sara Soltani Tehrani**, May Zin Hlaing, Joseph Fedro, Rami-James Aoun, Karishma Kundu, Sylvain Ferrandon, Matthew F. Kalady

Genomic Approaches to Define Tumor Biology and Clinical Stratification

Wednesday, April 22, 2026, 9 a.m. – noon

Section 26

Presentation number: 7278

Poster number: 18

Single-cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-cell Phenotypes in CLL Patients Treated with Ibrutinib

Authors: **Shanmugapriya Thangavadivel**¹, Jami Shaffer¹, Shrilekha Misra¹, Samon Benrashid¹, Britten Gordon¹, Alexander He¹, Wantong Li¹, Konur Oyman¹, Annika

Chura¹, Shelby Cabrera¹, Altan Turkoglu¹, Tzung-Huei Lai¹, Kerry Rogers², Seema Bhat², John C. Byrd³, James S. Blachly⁴, Jennifer A. Woyach⁵, Bradley Blaser⁶

Risk Prediction Modeling, Screening, Early Detection, and Preneoplastic and Tumor Markers

Wednesday, April 22, 2026, 9 a.m. – noon
Section 35

Presentation number: 7607

Poster number: 27

CT-Assessed Body Composition and Tumor Immunologic Characteristics in Patients with Endometrial Cancer

Authors: **Yidan Zhang**¹, Cuthbert Mario Mahenge¹, Jordan Krull², Rand Talal Akasheh¹, Laura Chambers³, Xuan Nguyen⁴, Ting-Yuan David Cheng¹

Late-Breaking Research: Experimental and Molecular Therapeutics 4

Wednesday, April 22, 2026, 9 a.m. – noon
Section 53

Presentation number: LB457

Poster number: 4

Ribonucleotide Reductase Inhibition Triggers Ferroptosis in Genetically Defined NSCLC
Authors: **Triparna Sen**